BRAF and neoplasm: Nonetheless, these data suggest that some patients with pre‐existing T cell responses to tumor antigens in their TIL may benefit from a brief course of BRAF+/−MEKi therapy prior to initiation of ICB as was seen in the “Sandwich Therapy Arm” of the Secombit Trial [31].